The BEA reports real disposable personal income rose 0.3% in October. Real PCE rose 0.3%. The PCE price index rose 0.1%. The hurricane impacts on income, outlays, and inflation appear to be tapering off according to the BEA’s report on Personal Income and Outlays for October. Real (inflation-adjusted) Disposable Personal Income (DPI) increased 0.3 percent in October. Real Personal Consumption Expenditures (PCE) increased 0.1 percent. The PCE price index increased 0.1 percent. Excluding food and energy, the PCE price index increased 0.2 percent. The $13.1 billion increase in real PCE in October reflected an increase of $11.4 billion in ...
There may be no better proxy for broad risk appetites right now than the price of Bitcoin. Gold is up 11% year-to-date; the S&P 500 is up 18%; the Nasdaq 100 is up a lofty 32%, but Bitcoin leaves them all in the dust. The cryptocurrency has climbed 900% so far during 2017. Predictably, this stellar performance has pulled in a massive amount of speculators hoping to find the path to easy riches. How do we know that so many folks have now jumped aboard the crypto express? Well, it’s difficult to quantify but Google trends tells us that “Bitcoin,” as a search term, is now more popular than “Beyonce,” “Taylor Swift” and “Kim K...
Well, all’s apparently well that ends well for U.S. equities which, on Thursday, are surging thanks at least in part to John McCain saying he’ll support the tax bill that’s currently being debated. A couple of things worth noting. The S&P is setting up for its eighth straight monthly gain – that would be the longest streak since January of 2007: For its part, the Dow is on pace for its best daily gain in nine months: But far more notable than that, the Dow’s eight-month winning streak would be the longest since July of 1995: Meanwhile, bonds are selling off – and “bigly.” 5-year yields now the highest since 2011: This is ...
It’s the merriest month of the year for the retail sector, courtesy of the holiday fervor and encouraging industry fundamentals. The frenzy of heavy discounts, promotions and free shipping are driving strong sales. Notably, the holiday season contributes about 25-40% to the sector’s annual sales. Per the latest data from National Retail Federation (NRF), more than 174 million Americans shopped during the Thanksgiving weekend (from Thanksgiving through Cyber Monday), much higher than the pre-holiday prediction of 164 million consumers. The group expects holiday sales through November and December to rise as much as 4% this year to $682 bil...
It’s the merriest month of the year for the retail sector, courtesy of the holiday fervor and encouraging industry fundamentals. The frenzy of heavy discounts, promotions and free shipping are driving strong sales. Notably, the holiday season contributes about 25-40% to the sector’s annual sales. Per the latest data from National Retail Federation (NRF), more than 174 million Americans shopped during the Thanksgiving weekend (from Thanksgiving through Cyber Monday), much higher than the pre-holiday prediction of 164 million consumers. The group expects holiday sales through November and December to rise as much as 4% this year to $682 bil...
The chart below is a way to visualize real GDP change since 2007. It uses a stacked column chart to segment the four major components of GDP with a dashed line overlay to show the sum of the four, which is real GDP itself. Here is the latest overview from the Bureau of Labor Statistics: Real gross domestic product (GDP) increased at an annual rate of 3.3 percent in the third quarter of 2017 (table 1), according to the “second” estimate released by the Bureau of Economic Analysis. In the second quarter, real GDP increased 3.1 percent. The GDP estimate released today is based on more complete source data than were available for the ...
The Chart of the Day belongs to AxoGen (AXGN). I found the regenerative medicine stock by using Barchart to sort today’s 52 Week New High list first for the highest Weighted Alpha, then for technical buy signals of 80% or more. I then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 11/20 the stock gained 7.61%. AxoGen Corp. is a regenerative medicine company engaged in the development and commercialization of technologies for peripheral nerve reconstruction and regeneration. It offers products for the repair of peripheral nerve injuries. AxoGen Corp was f...
A recurring pattern of the past few decades involves governments promising to limit their borrowing, only to discover that hardly anyone cares. So target dates slip, bonds are issued, and the debts keep rising. This time around the timing is especially notable, since eight years of global growth ought to be producing tax revenues sufficient to at least moderate the tide of red ink. But apparently not. In Japan, for instance, government debt is now 250% of GDP, a figure which economists from, say, the 1990s, would have thought impossible. Over the past decade the country’s leaders have proposed a series of plans for balancing the budget and ...
The headline data this month showed some growth in consumer income and spending – with expenditures year-over-year growth far outpacing income growth – and the savings rate remains historically low. Analyst Opinion of Personal Income and Expenditures The savings rate marginally improved but historically is extremely low. Consumer spending continues to far outpacing income – not good news. Although this month income grew faster than expenditures. The backward revisions this month were down. The market looks at current values (not real inflation adjusted) and was expecting (from Bloomberg):. Consensus Range Consensus Actual...
Biotechnology sector has corrected over 10%. Poor earnings of larger biotechs knocked the wind out of the sector. An imminent catalyst can push the sector higher, recovering recent losses and possibly make new 52-week highs. Mid cap and small cap companies well-positioned for gains Biotech Pulse The months of October and November have been unfavorable for biotechs as the sector has witnessed a sharp pullback. The Nasdaq Biotechnology Index (IBB), shown below, retreated 12% from its 52-week high posted in early October. Nasdaq Biotechnology Index (IBB) ~ November 2017 During the same time, while biotechs have suffered, major market indexes hav...